MedTrace Logo

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

NCT07458347 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-05-12

No results posted yet for this study

Summary

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutations.

Conditions

  • KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
  • KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
  • KRAS-mutant Colorectal Cancer (CRC)
  • Other KRAS-mutant Solid Tumors

Interventions

DRUG

KST-6051

KST-6051 will be administered orally as a tablet.

Sponsors & Collaborators

  • Kestrel Therapeutics, Inc.

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-21
Primary Completion
2027-06-30
Completion
2028-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07458347 on ClinicalTrials.gov